MedTrace Logo

Feasibility Study of BMAC Enhanced CABG

NCT01074099 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 5

Last updated 2016-01-18

Study results available
· View outcomes & findings →

Summary

Patients undergoing CABG will have 60 mL of bone marrow drawn, concentrated in a SmartPRep2 centrifuge and have the concentrated nucleated cells injected into areas of ischemic myocardium

Conditions

  • Congestive Heart Failure

Interventions

BIOLOGICAL

BMAC

Injection of BMAC into ischemic myocardium during CABG

PROCEDURE

CABG only

Control subjects will undergo CABG surgery without BMAC injection

Sponsors & Collaborators

Principal Investigators

  • Amit Patel, MD · University of Utah

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-28
Primary Completion
2013-04-30
Completion
2013-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01074099 on ClinicalTrials.gov